DOCSLIB.ORG

CHO Host Cell Proteins 3Rd Generation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CHO Host Cell Proteins 3Rd Generation CHO Host Cell Proteins 3rd Generation Immunoenzymetric Assay for the Measurement of CHO Host Cell Proteins Catalog # F550 Intended Use immunoenzymetric assay (ELISA) method employed in this kit overcomes the limitations of Western blots This kit is intended for use in determining the presence providing on the order of 100 fold better sensitivity. This of host cell protein impurities in products manufactured simple to use, objective, and semi-quantitative ELISA is by expression in the CHO cell line. The kit is for a powerful method to aid in optimal purification process Research and Manufacturing Use Only and is not development, process control, routine quality control, intended for diagnostic use in humans or animals. This and product release testing. This kit is “generic” in the is the 3rd Generation ELISA kit for CHO HCP detection. sense that it is intended to react with essentially all of the Cygnus Technologies continues to market two earlier HCPs that could contaminate the product independent generation kits, Cat #s F015 and CM015 for CHO HCP of the purification process. The antibodies have been detection. While those kits are broadly reactive to CHO generated in goats and affinity purified using CHO HCPs HCPs among all strains and have been successfully found in protein free conditioned media. Western blot, qualified for a range of drug substances, this 3rd both 1 & 2 dimensional, was used as a preliminary Generation assay uses an even more broadly reactive method and established that the antibodies reacted to antibody. The 3rd Generation Cat# F550 kit offers the majority of HCP bands resolved by the PAGE greater sensitivity and a more linear standard curve separation. Further characterization of coverage of the while incorporating a number of improvements to antibodies to the CHO CHP standards was overcome matrix interference and sample dilutional accomplished by a immunoaffinity chromatography linearity problems sometimes encountered in the two method we term Antibody Affinity Extraction (AAE). This older kits. method is superior to 2D Western blot and terms of sensitivity, specificity, and predictability of how the antibodies perform in the ELISA. The AAE fractionation Summary and Explanation of conditioned media derived HCP from 2 different CHO strains (CHO-S and K1) showed reactivity to ~1000 Expression of therapeutic proteins in CHO cells is a cost HCPs. For more information on AAE please contact our effective method for production of commercial quantities Technical Services department. of a drug substance. The manufacturing and purification Special procedures were utilized in the generation of process of these products leaves the potential for these antibodies to ensure that low molecular weight impurities by host cell proteins (HCPs) from CHO cells. and less immunogenic impurities as well as high Such impurities can reduce the efficacy of the molecular weight components would be represented. As therapeutic agent and result in adverse toxic or such, this kit can be used as a process development tool immunological reactions and thus it is desirable to to monitor the optimal removal of host cell impurities as reduce HCP impurities to the lowest levels practical. well as in routine final product release. Immunological methods using antibodies to HCPs This highly sensitive ELISA kit has been qualified for such as Western Blot and ELISA are conventionally testing of final product HCPs using actual in-process and accepted. While Western blot is a useful method aiding final drug substance samples from 5 different drug in the identity of HCPs, it suffers from a number of products including monoclonal antibodies and other limitations. Western blot is a complex and technique therapeutic proteins. The assay had sensitivity to detect dependent procedure requiring subjective interpretation HCP in all 5 final drug substances showing acceptable of results. Furthermore, it is essentially a qualitative dilutional linearity and spike recovery. Based on this method and does not lend itself to obtaining quantitative experience this assay should have application as a answers. The sensitivity of Western blot is severely multi-use assay for other products expressed in CHO limited by the volume of sample that can be tested, and cells. Each user of this kit is encouraged to perform a by interference from the presence of high concentrations similar qualification study to demonstrate it meets their of the intended product. While Western Blot may be able analytical needs. Provided this kit can be satisfactorily to detect HCPs in samples from upstream in the qualified for your samples, the application of a more purification process, it often lacks adequate sensitivity process specific assay may not be necessary in that and specificity to detect HCPs in purified downstream such an assay would only provide information redundant and final product. The microtiter plate to this generic assay. However, if your qualification Materials & Equipment Required studies indicate the antibodies in this kit are not sufficiently reactive with your process specific HCPs it But Not Provided may be desirable to also develop a more process specific ELISA. This later generation assay may require • Microtiter plate reader spectrophotometer with the use of a more specific and defined antisera. dual wavelength capability at 450 & 650nm. (If Alternatively, if the polyclonal antibody used in this kit your plate reader does not provide dual provides sufficient sensitivity and broad antigen wavelength analysis you may read at just the reactivity, it may be possible to substitute the standards 450nm wavelength.) used in this kit for ones made from the impurities that • Pipettors - 50L and 100L typically co-purify through your purification process and • Repeating or multichannel pipettor - 100L thus achieve better accuracy for process specific HCPs. • Microtiter plate rotator (400-600 rpm) The use of a process specific assay with more defined • Sample Diluent (recommended Cat # I028) antigens and antibodies in theory may yield better • Distilled water specificity, however such an assay runs the risk of being • 1 liter wash bottle for diluted wash solution too specific in that it may fail to detect new or atypical impurities that might result from some process Storage & Stability irregularity or change. For this reason it is recommended that a broadly reactive “generic” host cell protein assay be used as part of the final product purity analysis even • All reagents should be stored at 2C to 8C for when a process specific assay is available. If you deem stability until the expiration date printed on the kit. a more process specific assay is necessary, Cygnus • Reconstituted wash solution is stable until the Technologies is available to apply its proven expiration date of the kit. technologies to develop such antibodies and assays on • After prolonged storage, you may notice a salt custom basis. precipitate and/or yellowing of the wash concentrate. These changes will not impact assay Principle of the Procedure performance. To dissolve the precipitate, mix the wash concentrate thoroughly and dilute as The CHO assay is a two-site immunoenzymetric assay. directed in the ‘Preparation of Reagents’ section. Samples containing CHO HCPs are reacted Reconstituted wash solution is stable until the simultaneously with a horseradish peroxidase (HRP) expiration date of the kit. enzyme labeled anti-CHO antibody (goat polyclonal) in microtiter strips coated with an affinity purified capture anti-CHO antibody. The immunological reactions result Precautions in the formation of a sandwich complex of solid phase antibody-HCP-enzyme labeled antibody. The microtiter • For Research or Manufacturing use only. strips are washed to remove any unbound reactants. • Stop reagent is 0.5M H2SO4. Avoid contact with The substrate, tetramethylbenzidine (TMB) is then eyes, skin, and clothing. reacted. The amount of hydrolyzed substrate is read on • This kit should only be used by qualified a microtiter plate reader and is directly proportional to technicians. the concentration of CHO HCPs present. Preparation of Reagents Reagents & Materials Provided Component Product # • Bring all reagents to room temperature. Anti-CHO:HRP F551 • Dilute wash concentrate to 1 liter in distilled water, Affinity purified goat antibody conjugated to HRP label with kit lot and expiration date, and store at in a protein matrix with preservative. 1x12mL 4C. Anti-CHO coated microtiter strips F552* 12x8 well strips in a bag with desiccant Procedural Notes CHO HCP Standards F553 CHO HCPs in bovine serum albumin with preservative. Standards at 0, 1, 3, 12, 40, and 1. Complete washing of the plates to remove excess 100ng/mL. 1 mL/vial unreacted reagents is essential to good assay Stop Solution F006 reproducibility and sensitivity. We advise against the use 0.5M sulfuric acid. 1x12mL of automated or other manually operated vacuum TMB Substrate F005 aspiration devices for washing plates as these may 3,3’,5,5’ Tetramethylbenzidine. 1x12mL result in lower specific absorbances, higher non-specific Wash Concentrate (20X) F004 absorbance, and more variable precision. The manual Tris buffered saline with preservative. 1x50mL wash procedure described below generally provides *All components can be purchased separately except # F552. lower backgrounds, higher specific absorbance, and better precision. If duplicate CVs are poor, or if the 800-F550, Rev. 4, 27JUN2018 CHO HCP 3G ELISA Product Insert 2 absorbance of the ‘0’ standard is greater
Load more

Recommended publications
  • Assessment Report COVID-19 Vaccine Astrazeneca EMA/94907/2021
    29 January 2021 EMA/94907/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report COVID-19 Vaccine AstraZeneca Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ..................................................................................... 7 1.2. Steps taken for the assessment of the product ........................................................ 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ........................................................................................ 12 2.1.2. Epidemiology and risk factors ........................................................................... 12 2.1.3. Aetiology and pathogenesis .............................................................................
    [Show full text]
  • Quantification of Host Cell Protein Impurities Using the Agilent 6495C Triple Quadrupole LC/MS
    Application Note Pharma & Biopharma Quantification of Host Cell Protein Impurities using the Agilent 6495C Triple Quadrupole LC/MS Author Abstract Linfeng Wu Agilent Technologies, Inc., This Application Note describes a method for sub-ppm host cell protein quantification in a mAb product. The workflow featured an Agilent AssayMAP Bravo platform, an Agilent 1290 Infinity II LC, and an Agilent 6495C triple quadrupole LC/MS. Introduction Experimental Sample preparation The mAb sample was subjected to Host cell protein (HCP) impurities are Instrumentation denaturation, reduction, alkylation, and low-level protein impurities derived • Agilent AssayMAP Bravo system trypsin digestion using the AssayMAP from the host organisms during the (G5571AA) Bravo system. SIL peptides were biopharmaceutical manufacturing combined at equal molar concentration • Agilent 1290 Infinity II LC including: process. Due to their potential to affect and spiked into the sample digest at product safety and efficacy, HCPs • Agilent 1290 Infinity II high-speed eight different levels (6.25, 12.5, 25, 62.5, must be monitored and controlled in pump (G7120A) 125, 250, 12,500, and 125,000 amol/µg drug products according to regulatory • Agilent 1290 Infinity II per SIL peptide) for quantitative analysis. requirements1. Traditionally, the multisampler (G7167B) with enzyme-linked immunosorbent assay LC/MS analysis sample cooler option (option 100) (ELISA) is the standard method for Samples were analyzed by the 6495C quantifying HCPs in protein therapeutics. • Agilent 1290 Infinity II triple quadrupole LC/MS in dMRM However, ELISA lacks the specificity thermostatted column mode using a nine-minute LC gradient. and coverage to identify and quantify compartment (G7116B) Tables 1 and 2 list detailed experimental individual HCPs.
    [Show full text]
  • Host Cell Protein Assays
    BIOLOGICS TESTING SOLUTIONS Host Cell Protein Assays Charles River works with clients to develop project-specific and platform-specific host cell protein (HCP) assays. Additionally, we serve clients with the characterization of commercially available kits and coverage determination. The type of assay required to determine HCP content is dependent upon the phase of product development. In early process development and early clinical phases, generic assays are normally acceptable. However, once the biopharmaceutical is used in Phase III clinical studies, a validated, product-specific HCP assay is usually required. We can provide clients with assay development and validation, regardless of whether they are in preclinical development or embarking on Phase III studies. What Are Host Cell Proteins? Host cell proteins (HCP) represent a heterogeneous pool of contaminant proteins that are an inevitable impurity of biopharmaceuticals, regardless of whether they are produced by recombinant fermentation or extracted from natural sources. Even after multiple sophisticated purification steps, HCPs may co-purify, or “hitchhike,” with the product, and thus need to be characterized and quantified in drug substance and in downstream purification process (DSP) intermediates. The risk for adverse effects such as immunogenic reaction does not necessarily correlate with the amount of certain host cell proteins, and even traces of an HCP can be highly immunogenic, or may adversely impact product quality over its shelf life. Traditional protein detection methods such as HPLC and total protein stains are not suitable for HCP detection due to insufficient sensitivity and specificity. Consequently, optimized immunoassays (ELISA) and mass spectrometry (MS) methods have established themselves as the methods of choice for the measurement and characterization of HCPs.
    [Show full text]
  • Development of Host Cell Protein Impurities Quantification Methods by Mass Spectrometry to Control the Quality of Biopharmaceuticals Gauthier Husson
    Development of host cell protein impurities quantification methods by mass spectrometry to control the quality of biopharmaceuticals Gauthier Husson To cite this version: Gauthier Husson. Development of host cell protein impurities quantification methods by mass spec- trometry to control the quality of biopharmaceuticals. Analytical chemistry. Université de Strasbourg, 2017. English. NNT : 2017STRAF066. tel-01730667 HAL Id: tel-01730667 https://tel.archives-ouvertes.fr/tel-01730667 Submitted on 13 Mar 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITÉ DE STRASBOURG ÉCOLE DOCTORALE DES SCIENCES CHIMIQUES UMR 7178 THÈSE présentée par : Gauthier HUSSON soutenue le : 10 novembre 2017 pour obtenir le grade de : Docteur de l’université de Strasbourg Discipline / Spécialité : Chimie / Chimie Analytique DEVELOPMENT OF HOST CELL PROTEIN IMPURITIES QUANTIFICATION METHODS BY MASS SPECTROMETRY TO CONTROL THE QUALITY OF BIOPHARMACEUTICALS THÈSE dirigée par : Dr. VAN DORSSELAER Alain Directeur de recherche, CNRS, Université de Strasbourg, France Pr. BRACEWELL Daniel Professor, University College London, United Kingdom RAPPORTEURS : Dr. FERRO Myriam Directeur de recherche, CEA, Grenoble, France Dr. O’HARA John Director, Characterisation, UCB, Slough, United Kingdom AUTRES MEMBRES DU JURY : Dr. GERVAIS Annick Director PCMD I, ASB, UCB, Braine l’Alleud, Belgium Dr.
    [Show full text]
  • HOST-CELL PROTEIN TESTING: Perspective of Current and Future Techniques
    HOST-CELL PROTEIN TESTING: Perspective of Current and Future Techniques April 23, 2018 Dr. Min Zhao Director, Analytical Services for Biologics Products – CMC Services TABLE OF CONTENTS Introduction............................................................................................................................. 3 Residual HCPs Are Problematic..................................................................................... 3 Regulators Key in on HCPs............................................................................................. 3 HCPs are Abundant, Heterogeneous and Hard to Detect.......................................... 4 Several Testing Options Exist............................................................................................. 4 Best Practices Are EmergIng with New Testing Methods............................................ 5 MS Technology Is the Way of the Future.................................................................... 6 2. VISIT US AT: frontagelab.com © 2018 Frontage Laboratories, Inc. HOST-CELL PROTEIN TESTING: Perspective of Current and Future Techniques Introduction Biologics are produced using living cells or organisms. The living cells can be derived from prokaryotic, eukaryotic, and mammalian cells that are genetically engineered to encode the protein of therapeutic use. During the protein expression process, thousands of endogenous proteins, or host-cell proteins (HCPs), are produced and needed to maintain cellular function and regulation, as well as the protein of interest.
    [Show full text]
  • Protein Aggregation and Host Cell Protein
    INVESTIGATING THE IMMUNOGENICITY OF THERAPEUTIC PROTEINS: PROTEIN AGGREGATION AND HOST CELL PROTEIN IMPURITIES A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health 2016 Kirsty D Ratanji Table of Contents 1 Introduction 15 1.1 Review article: Immunogenicity of therapeutic proteins: Influence of aggregation 15 1.1.1 Abstract 17 1.1.2 Introduction 18 1.1.3 Protein aggregation 19 1.1.4 Methods to reduce aggregation 24 1.1.5 Immunogenicity of biotherapeutics 26 1.1.6 Clinical examples of aggregation associated immunogenicity 32 1.1.7 Screening for aggregation and immunogenicity 38 1.1.8 Concluding remarks 44 1.2 Introduction (cont’d) 45 1.2.1 Immunogenicity testing 45 1.2.2 Biophysical methods for aggregate analysis 52 1.2.3 Thesis aims 59 1.3 Alternative format 63 2 Paper 1: Producing and characterising subvisible protein aggregates for immunogenicity studies 65 2.1 Abbreviations 66 2.2 Abstract 67 2.3 Introduction 68 2.4 Methods 71 2.5 Results 76 2.6 Discussion 86 2 2.7 Acknowledgements 92 2.8 Appendix 93 2.9 References 93 3 Paper 2: Subvisible aggregates of immunogenic proteins promote a Th1-type response 97 3.1 Abstract 99 3.2 Introduction 100 3.3 Materials and Methods 103 3.4 Results 108 3.5 Discussion 124 3.6 Acknowledgements 129 3.7 Supplementary data 130 3.8 References 131 4 Paper 3: Influence of E.coli chaperone DnaK on protein immunogenicity 136 4.1 Abbreviations 138 4.2 Abstract 139 4.3 Introduction 140 4.4 Methods 143 4.5 Results 148 4.6 Discussion
    [Show full text]
  • MSD 96-Well MULTI-ARRAY Bio-Process Assay Summary
    MSD® 96-Well MULTI-ARRAY® Bio-Process Assay CHO Host Cell Protein Assay Summary MSD’s bioprocess assays are designed for single and multiplex measurements of common bioprocess contaminants. Assays for several common contaminants including insulin, methotrexate (MTX), host cell proteins, and protein A are currently available. This insert describes how to run the CHO Host Cell Protein assay independently. MSD offers additional kits for CHO Host Cell Protein multiplexed with Protein A or with insulin and MTX. Comments on the assay Currently, MSD offers assays for host cell proteins from Chinese hamster ovary (CHO) and E.Coli cells. The polyclonal antibodies used in these immunoassays were raised against a lysate of washed cells. These assays can be run either with the HCP Calibrator supplied or with a customer-supplied Calibrator (e.g. from a mock bioprocess run). Calibrators provided by MSD for HCP assays are solubilized with a detergent. The Diluent 21 that the Calibrators are diluted in includes this detergent. FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES. 17370-v3-2009Sep Reagents Provided Storage MULTI-ARRAY or 96-well MSD plate spotted with ® 2-8 oC MULTI-SPOT Plate specific capture antibodies Detection Antibodies labeled with CHO HCP Detection SULFO-TAG reagent. These 2-8 oC Antibody antibodies are supplied at 50X concentration Read Buffer T 4X Read Buffer T with surfactant RT Buffered solution containing blocking Diluent 21 and stabilizing agents in addition to ≤ -10 oC detergents CHO HCP Calibrator
    [Show full text]
  • EUROPEAN PHARMACOPOEIA Free Access to Supportive Pharmacopoeial Texts in the Field of Vaccines for Human Use During the Coronavirus Disease (COVID-19) Pandemic
    EUROPEAN PHARMACOPOEIA Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease (COVID-19) pandemic Updated package - October 2020 Published in accordance with the Convention on the Elaboration of a European Pharmacopoeia (European Treaty Series No. 50) European Directorate Direction européenne for the Quality de la qualité of Medicines du médicament & HealthCare & soins de santé Council of Europe Strasbourg Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease (COVID-19) pandemic Updated package The EDQM is committed to supporting users during the coronavirus disease (COVID-19) pandemic – as well as contributing to the wider global effort to combat the virus – by openly sharing knowledge and providing access to relevant guidance/standards. To support organisations involved in the development, manufacture or testing of COVID-19 vaccines worldwide, many of which are universities and small and medium-sized enterprises, the EDQM is offeringte mporary free access to texts of the European Pharmacopoeia (Ph. Eur.) in the field of vaccines. This package includes quality standards for vaccines which developers can take into account to help build appropriate analytical control strategies for their COVID-19 candidate vaccines and ensure the quality and safety of the final product. Application of such quality requirements may ultimately help to facilitate regulatory acceptance of a subsequent marketing authorisation application. For ease of reading, a summary table listing the pharmacopoeial texts, with information regarding the vaccine types or vaccine platforms concerned (e.g. live attenuated viral vaccine, recombinant viral-vectored vaccines) is provided.
    [Show full text]
  • Bioprecess/Vaccine (HCP) Contaminats Detection and Removal ELISA Kits
    Bioprecess/Vaccine (HCP) Contaminats Detection and Removal ELISA Kits Vaccines are among the greatest achievements of modern medicine. Vaccines are derived from either whole cells (bacteria or virus; live or attenuated) grown in chick embryo or in mammalian host cells. Subunit vaccines may be recombinant proteins expressed in E. coli or year or other host cells. Depending upon the source of the material, purified active vaccine components may still have remnants of the host (cellular proteins or host cell proteins or HCP, culture medium proteins (Fetal bovine serum or BSA, or Fetuin etc). These extraneous proteins or components are typically known host cell contaminants. FDA requires that the finished vaccine material be tested for the appropriate contaminant and their concentration kept to an acceptable level. Many additives or excipients (Proteins, bacteriostatic agents or adjuvants) are added to stabilize the vaccines or to enhance antigenicity (adjuvants). Elevated levels of the contaminants may be allergenic (ovalbumin) or carry risk of prophylaxis due to the production of antibodies to foreign proteins or risk of animal or human derived diseases. Excipient/Contaminants Use Vaccine (Brand) Albumin Egg (Ovalbumin or OVA) Rabies Virus Grown Rabies (RabAvert) chick embryo fibroblast Albumin, Human serum (HSA) Growth medium, protein Measles (attenuvax), MMR (MMR-II), Mumps (Mumpsvax), Rabies (Imovax), stabilizer Rubella (Meruvax) Albumin, Bovine serum (BSA) Growth medium, protein Hepatitis A (Harvix, Vaqta); Measles (Attenuvax), MMR
    [Show full text]
  • Immunoenzymetric Assay for the Measurement of MRC5 Host Cell Proteins Catalog # F300
    MRC5 Host Cell Proteins Immunoenzymetric Assay for the Measurement of MRC5 Host Cell Proteins Catalog # F300 Intended Use with essentially all of the HCPs that could pollute the product independent of the purification process. The This kit is intended for use in determining the presence antibodies have been generated against and affinity of MRC5 host cell protein impurities in products purified using a mild lysate washed of MRC5 cells to manufactured by recombinant expression in MRC5 cells. obtain HCPs typically encountered in your initial product The kit is for Research and Manufacturing Use Only recovery step. Western blot was used as a preliminary and is not intended for diagnostic use in humans or method and established that the antibodies reacted to animals. the majority of HCP bands resolved by the PAGE separation. If you have need of a more sensitive and specific method to demonstrate reactivity to individual Summary and Explanation HCPs in your samples If you have a need of a more sensitive method to demonstrate coverage to HCPs in Recombinant protein expression or virus replication in your process Cygnus Technologies recommends a the MRC5 cell line is a cost effective method for method that is superior to Western blot called Antibody production of vaccines or other therapeutic proteins. Affinity Extraction (AAE). AAE is has greatly increased Many of these products are intended for use as sensitivity and specificity to Western blot which makes it therapeutic agents in humans and animals and as such a better predictor of how the antibodies will perform in must be highly purified. The manufacturing and the ELISA.
    [Show full text]
  • Protein Metrics Solutions
    Vendor Neutral Host Cell Protein Analysis Regulator Positions on HCPs – VERY CLEAR • Regulators classify residual host cell proteins (HCPs) as “process-related impurities” [ICH Q6B, Q2B]. • ‘Finding’, ‘measuring’ and ‘monitoring’ are key guideline elements • EMA from 1997: ‘The ability of the purification process to remove other specific contaminants such as host-cell proteins … should be demonstrated’ • USFDA biosimilar guidelines 2012: “In all cases, the chosen analytical procedures should be adequate to detect, identify, and accurately quantify biologically significant levels of impurities (see ICH Q2B)”. http://www.fda.gov/downloads/drugs/guidancecomplianceregula http://www.ema.europa.eu/docs/en_GB/document_librar toryinformation/guidances/ucm073488.pdf y/Scientific_guideline/2009/09/WC500003947.pdf Before there was Mass Spectrometry… Points at which Cost Savings Can be Made with HCP Analysis Upstream: ‘Catalogue’ of HCPs/ contaminants – Save Millions of dollars over product lifecycle and multiple cell lines Image source: Ratcliff and Preisig 2013; BioProcess International; http://www.bioprocessintl.com/journal/2013/April/Ad vances-in-Sensor-Technology-Improve- Biopharmaceutical-Development-341848 Points at which Cost Savings Can be Made with HCP Analysis Upstream: ‘Catalogue’ of HCPs/ contaminants – Save Millions of dollars over product lifecycle and multiple cell lines Improved ELISA assays (better specificity) – hundreds of thousands of dollars in avoided recall per batch Image source: Ratcliff and Preisig 2013; BioProcess International;
    [Show full text]
  • HOST CELL PROTEIN ANALYSIS ELISA Or LC-MS/MS
    HOST CELL PROTEIN ANALYSIS ELISA or LC-MS/MS 1 host cell protein Host cell protein (HCP) is a protein produced or encoded by a host cell during the synthesis of recombi- nant therapeutic proteins. Recombinant therapeutic proteins are usually produced by genetically modified prokaryotic or eukaryotic host cells using cell culture or fermentation techniques. Genetic engineering enables host cells to be transformed to selectively express the target protein. In the process of recombi- nant protein production, host cells also jointly produce proteins related to normal cell functions, such as cell growth, proliferation, survival, gene transcription, protein synthesis, and so on. Due to cell apoptosis, death, and lysis, other non-essential proteins can also be released into the cell culture medium. As a foreign protein, residual HCP in biological products is low in content, but could still trigger the body's immune response to varying degrees, and ultimately lead to allergic reactions or other adverse reactions. HCP constitutes the main part of process-related impurities in the production process of biological agents. The amount of residual HCP in a drug is usually considered a critical quality attribute (CQA) because it may affect product safety and efficacy. Therefore, the regulatory requirement is to monitor the removal of HCP in biopharmaceuticals during the development of bioprocesses. 2 method of host cell protein analysis ELISA LC-MS/MS Enzyme-Linked ImmunoSorbent Assay (ELISA) ELISA developed using polyclonal antibodies produced against parental cell lysates or cell culture superna- tants can detect most HCP species. Enzyme-Linked ImmunoSorbent Assay (ELISA) is the most widely used HCP detection method, but this technique has limitations.
    [Show full text]